BG MEDICINE, INC. Inactive Instrument
BG Medicine, Inc. Share Price Other OTC
Equities
BGMD
US08861T2069
Pharmaceuticals
| Sales 2014 | 27.87L 23Cr | Sales 2015 | 15.66L 13Cr | Capitalization | 40.61L 34Cr |
|---|---|---|---|---|---|
| Net income 2014 | -80L -67Cr | Net income 2015 | -50L -42Cr | EV / Sales 2014 | 5.28 x |
| Net cash position 2014 | 11.63L 9.7Cr | Net cash position 2015 | 15.25L 13Cr | EV / Sales 2015 | 1.62 x |
| P/E ratio 2014 |
-1.87
x | P/E ratio 2015 |
-0.5
x | Employees | - |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Hall
DFI | Director of Finance/CFO | 73 | 03/13/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry Wilcox
CHM | Chairman | 69 | 12/15/12 |
Jeffrey R. Luber
BRD | Director/Board Member | 57 | 04/16/04 |
James O'Connor
BRD | Director/Board Member | 67 | 17/15/17 |
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -48.35% | 97Cr | |
| -7.10% | 6.48Cr |
